Heparin and its derivatives: Challenges and advances in therapeutic biomolecules

29Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

Abstract

Heparin has been extensively studied as a safe medicine and biomolecule over the past few decades. Heparin derivatives, including low-molecular-weight heparins (LMWH) and heparin pentasaccharide, are effective anticoagulants currently used in clinical settings. They have also been studied as functional biomolecules or biomaterials for various therapeutic uses to treat diseases. Heparin, which has a similar molecular structure to heparan sulfate, can be used as a remarkable biomedicine due to its uniquely high safety and biocompatibility. In particular, it has recently drawn attention for use in drug-delivery systems, biomaterial-based tissue engineering, nanoformulations, and new drug-development systems through molecular formulas. A variety of new heparin-based biomolecules and conjugates have been developed in recent years and are currently being evaluated for use in clinical applications. This article reviews heparin derivatives recently studied in the field of drug development for the treatment of various diseases.

Cite

CITATION STYLE

APA

Banik, N., Yang, S. B., Kang, T. B., Lim, J. H., & Park, J. (2021, October 1). Heparin and its derivatives: Challenges and advances in therapeutic biomolecules. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms221910524

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free